CLINICAL_TRIALS
trial_result
· 2024-06-14
Clinical Trial Update: China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)
Summary
A completed real-world study in China evaluating IDegAsp (insulin degludec/insulin aspart) for type 2 diabetes.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED